Roche: mixed data in breast cancer trial
(CercleFinance.com) - On Saturday Genentech, the biotech subsidiary of the Swiss giant Roche, announced mixed results for several studies concerning its immunotherapy Tecentriq in the treatment of triple negative breast cancer, a form of aggressive cancer often diagnosed at an advanced stage.
The pharmaceutical group points out that the results of a first phase III study showed that Tecentriq, combined with chemotherapy, had improved the complete pathological response (pCR, "pathological complete response") of patients treated versus those who took placebo and chemotherapy.
However, another phase III study evaluating the combination of Tecentriq and paclitaxel in the treatment of triple negative PD-L1 expression breast cancer did not meet its main primary endpoint, i.e. an improved survival of patients without disease progression.
Roche presented these results at the European Society of Medical Oncology (ESMO) Congress, held this year in "virtual" format due to the Covid-19 pandemic.
It should also be noted that this morning the Dutch group Scenic Biotech, which is specialised in genetic modifiers, announced the signing of a partnership deal several years with Genentech for the discovery of new drugs.
Copyright (c) 2020 CercleFinance.com. All rights reserved.